No Detail Found!

Delayed Hydroxyurea Use in Adult Female Sickle Cell Anaemia: A Missed Long-Term Management Opportunity

Author(s)
Saeed M Kabrah Department of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia
Abstract
Objectives: Sickle Cell Anaemia (SCA) is a lifelong haemoglobinopathy marked by chronic haemolysis, recurrent vaso-occlusive crises (VOCs), and progressive organ damage. Hydroxyurea is a well-established disease-modifying therapy; however, its use in adults remains inconsistent, particularly in regions with limited access to specialised care. Case Presentation: We describe a 35-year-old Saudi woman with homozygous SCA who presented with acute back and limb pain unresponsive to standard analgesia. She reported frequent admissions and transfusions but had never received hydroxyurea. On admission, she was tachypneic with oxygen desaturation (SpO2 80%) and borderline hypotension. Laboratory evaluation revealed normocytic anaemia (Hb 8.2 g/dL), elevated lactate dehydrogenase (317 U/L), reticulocytosis (6.12%), and severe vitamin D deficiency (7 ng/mL). Hydroxyurea (500 mg/day) was initiated in conjunction with folic acid and vitamin D supplementation. At the two-week follow-up, her pain score improved from 6/10 to 3/10, her energy levels increased, oxygen saturation stabilised, and laboratory monitoring demonstrated reduced haemolysis with stable haemoglobin levels. Discussion and conclusion: This case illustrates how delayed initiation of hydroxyurea represents a missed therapeutic opportunity in adult SCA, particularly among women beyond childbearing age. The timely use of hydroxyurea, combined with the correction of comorbidities such as vitamin D deficiency, can improve quality of life. Standardised pathways and systematic reassessment are urgently needed to ensure consistent adult SCA care.
Publication Details
Page(s) 89-95
Published Journal: Journal of Pioneering Medical Sciences, Volume: 14, Issue: 9, Year: 2025

Request the full text from PASTIC

Keywords
Case report, Saudi Arabia, Sickle cell anaemia, Hydroxyurea, Vaso-occlusive Crisis
References
Egesa W.I. .2022 .Sickle Cell Disease in Children and Adolescents: A Review of the Historical, Clinical, and Public Health Perspective of Sub-Saharan Africa and Beyond. International Journal of Pediatrics, : .
Almanasif M.A.,Newborn M.A. .2024 .Screening of Hemoglobinopathies Using Mass Spectrometry in Saudi Arabia. , : .
Alharbi R.A. . .The Prevalence of Neonatal Anemia in Al Baha, Saudi Arabia: A Retrospective Observational Study. The Egyptian Journal of Haematology, 48(2023) : 253-259.
Makkawi M. .2021 .. Hemoglobinopathies: An Update on the Prevalence Trends in Southern Saudi Arabia.” Saudi Medical Journal, 42(2021) : 784-789.
Alghamdi F.A. . .Risk Factors for Acute Chest Syndrome among Children with Sickle Cell Anemia Hospitalized for Vaso-Occlusive Crises. Scientific Reports, 14(2024) : 5978.
Sabina M. .2024 .Vaso-Occlusive Crises in Sickle Cell Trait Patients with Blood Loss Anemia: A Report of Two Cases. , 16(3) : .
van Tuijn ,C.F.J. .2017 .Prospective Evaluation of Chronic Organ Damage in Adult Sickle Cell Patients: A Seven-Year Follow-Up Study. American Journal of Hematology, 92(10) : E584-E590.
Barton F. .2003 .Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia. ” JAMA, 289(13) : 1645-1651.
Gohal G.A. .2022 .Utilization of Hydroxyurea among Patients Diagnosed with Sickle Cell Disease in Jazan, Saudi Arabia. Patient Preference and Adherence, : 3059-3067.
Pizzo A. . .Provider Prescription of Hydroxyurea in Youth and Adults with Sickle Cell Disease: A Review of Prescription Barriers and Facilitators. British Journal of Haematology, 203(2023) : 712-721.
Alherz I.H. .2024 .Utilization and Perceptions of Hydroxyurea Therapy among Adult Patients with Sickle Cell Disease in Al Ahsa, Saudi Arabia: A Cross-Sectional Study. ” Cureus, 16(7) : .
Kroner B.L. . .Pregnancy Outcomes with Hydroxyurea Use in Women with Sickle Cell Disease. American Journal of Hematology, 97(2022) : 603-612.
Rubio Lopez,M. Lopez,Marina and M. Arguello .2024 .The Current Role of Hydroxyurea in the Treatment of Sickle Cell Anemia. ” Journal of Clinical Medicine, 13(21) : 6404.
Yawn B.P. .2014 .. Management of Sickle Cell Disease: Summary of the 2014 Evidence-Based Report by Expert Panel Members.” JAMA, 10517(10) : 1033-1048.
Borhade M.B.,Patel P.,Kondamudi N.P. .2024 .. StatPearls Publishing, : .
Weaver S.B. . .Contemporary Management and Prevention of Vaso-Occlusive Crises (VOCs) in Adults with Sickle Cell Disease. ” Journal of Pharmacy Practice, 36(2023) : 139-148.
Sahu A. .2022 .Defining Vitamin D Deficiency in Patients with Sickle Cell Disease: A Meta-Analysis. ” Journal of Parathyroid Disease, 11154(2022) : e11154.
Piel F.B. . .Defining Global Strategies to Improve Outcomes in Sickle Cell Disease: A Lancet Haematology Commission.” The Lancet Haematology. , 3026(23) : 00171-1.
Ware R.E. .2017 .. Sickle Cell Disease.” The Lancet, 6736(17) : 30193-9.
Pule G.D. .2015 .A Systematic Review of Known Mechanisms of Hydroxyurea-Induced Fetal Hemoglobin for Treatment of Sickle Cell Disease. ” Expert Review of Hematology, 1063428(2015) : 669-679.
Plett R. . .Empowering Patients with Sickle Cell Anemia and Their Families through Innovative Educational Methods. EJHaem, 4(2023) : 678-955.
Geway G.,Ferdjallah A.,Supplement 1 .2024 .Sickle Cell Patient Education Materials. ” Journal of Sickle Cell Disease, 1 : .
King K. .2023 .Barriers to Medication Adherence in Sickle Cell Disease: A Comprehensive Theory-Based Evaluation Using the COM-B Model. Pediatric Blood & Cancer, : .
Alkanhal H. .2014 .Adherence to Hydroxyurea Therapy in Patients with Sickle Cell Disease. ” Journal of Blood Disorders and Transfusion, 5(2) : 1000202-9864.
0

Citations

0

Downloads

45

Views